Stay updated on Adaptive Dosing of Ipilimumab and Nivolumab Clinical Trial
Sign up to get notified when there's something new on the Adaptive Dosing of Ipilimumab and Nivolumab Clinical Trial page.

Latest updates to the Adaptive Dosing of Ipilimumab and Nivolumab Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.SummaryDifference4%
- Check21 days agoChange DetectedVersion label updated from v3.0.2 to v3.1.0; no other content changes.SummaryDifference0.1%
- Check28 days agoNo Change Detected
- Check36 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2, and the 'Back to Top' element was removed.SummaryDifference0.2%
- Check43 days agoChange DetectedThe web page has been updated to version 3.0.1, which includes a new pilot study on programmed death ligand-1 PET imaging in melanoma patients.SummaryDifference2%
- Check50 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location, as well as various new medical terms related to proteins and antibodies. Notably, previous references to certain genetic resources and specific antineoplastic agents have been removed.SummaryDifference3%
- Check64 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
Stay in the know with updates to Adaptive Dosing of Ipilimumab and Nivolumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Adaptive Dosing of Ipilimumab and Nivolumab Clinical Trial page.